3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Melanoma
4
Carcinoma, Renal Cell
3
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Merkel Cell
1
Interventions
Temozolomide
10
Irinotecan
8
Cyclophosphamide
7
dinutuximab
5
aldesleukin
4
Interleukin-2
4
Granulocyte-Macrophage Colony-Stimulating Factor
4
sargramostim
3
fludarabine
3
Topotecan
3
Melphalan
3
Isotretinoin
3
Filgrastim
3
gallium Ga 68 dotatate
2
Vincristine
2
TPI-287
2
Peripheral Blood Stem Cell Transplantation
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Carboplatin
2
venetoclax
1
trametinib
1
thymoglobulin
1
talazoparib
1
sonidegib
1
silmitasertib
1
plerixafor
1
olaparib
1
naxitamab
1
lutetium Lu 177 dotatate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Neuroblastoma
×
bempegaldesleukin
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts